BILL ANALYSIS �
-----------------------------------------------------------------
|SENATE RULES COMMITTEE | SCR 17|
|Office of Senate Floor Analyses | |
|1020 N Street, Suite 524 | |
|(916) 651-1520 Fax: (916) | |
|327-4478 | |
-----------------------------------------------------------------
THIRD READING
Bill No: SCR 17
Author: Anderson (R) and Hernandez (D)
Amended: As introduced
Vote: 21
SUBJECT : Cancer Prevention Week
SOURCE : Author
DIGEST : This resolution designates April 7 to 13, 2013,
inclusive, as Cancer Prevention Week, and encourages individuals
to participate in the Cancer Prevention Study - 3.
ANALYSIS : This resolution makes the following legislative
findings:
1. The American Cancer Society's Cancer Prevention Study - 3 is
recruiting 300,000 adults across the United States to help
better understand the genetic, environmental, and lifestyle
factors that cause or prevent cancer.
2. In 2013, more than 1,342,000 people will live with a history
of cancer, nearly 144,800 will be diagnosed with cancer, and
nearly 55,500 will die of cancer.
3. From 1988 to 2010, cancer incidence rates in California
declined by 9%.
4. Despite these improvements, nearly one in two Californians
born today will develop cancer at some point in their lives,
and it is likely that one in five will die of the disease.
CONTINUED
SCR 17
Page
2
5. The exact reasons why one individual develops cancer, and
another individual with very similar life experiences does
not, are beyond scientific understanding. Just as there are
many different types of cancers, there are many factors that
contribute to an individual's risk of developing cancer.
6. The goal of the American Cancer Society's Cancer Prevention
Study - 3 is to better understand those factors that
contribute to cancer.
This resolution designates April 7 to 13, 2013, inclusive, as
Cancer Prevention Week, and encourages individuals to
participate in the Cancer Prevention Study - 3.
FISCAL EFFECT : Fiscal Com.: No
RM:k 3/13/13 Senate Floor Analyses
SUPPORT/OPPOSITION: NONE RECEIVED
**** END ****